Hepatitis C Support Group
Hepatitis C is a blood-borne viral disease which can cause liver inflammation, fibrosis, cirrhosis and liver cancer. The hepatitis C virus (HCV) is spread by blood-to-blood contact with an infected person's blood. Many people with HCV infection have no symptoms and are unaware of the need to seek treatment. Hepatitis C infects an estimated 150-200 million people worldwide.
The guidelines make recommendations for all genotypes, and include all direct-acting antivirals that are expected to be licensed in Europe during 2014, including the protease inhibitor simeprevir (Olysio) and the NS5A inhibitor daclatasvir. Simeprevir is likely to receive marketing approval in May 2014 and daclatasvir in September 2014. Bristol-Myers Squibb, the developer of daclatasvir, has anticipated the European move towards a 'mix-and-match' approach by applying for a licence for daclatasvir alone in Europe. In the United States, it is seeking a licence for daclatasvir in combination with asunaprevir.
This mix & match approach may be adopted in the USA as well & that would be awesome IMHO!
http://www.aidsmap.com/European-liver-specialists-recommend-mix-and-match-approach-to-new-hepatitis-C-drugs/page/2846012/
This mix & match approach may be adopted in the USA as well & that would be awesome IMHO!
http://www.aidsmap.com/European-liver-specialists-recommend-mix-and-match-approach-to-new-hepatitis-C-drugs/page/2846012/
I wonder what other disease has drugs approved in COMBO only??? I can't think of any. Was that done with HIV???
For RA, for instance, methatrexate is RECOMMENDED with most all biologicals (Humira, Enbrel, Orencia, etc.) but, you also be prescribed meth alone or any of the bios alone.